


**Relationship between gamma-interferon and interleukin-17 in *Chlamydia trachomatis* reactive arthritis**

Sirs,  
 Reactive arthritis (ReA) is triggered by urethritis or enteritis causing pathogens (1). The presence of IL-17 has been reported in ReA joints following a history of diarrhea (2) but the presence of IL-17 in *C. trachomatis* ReA joints has never been investigated. The objective of the study described herein was to determine the levels of IL-17 and IL-17-modulating cytokines in the synovial fluid (SF) from *C. trachomatis* ReA, rheumatoid arthritis (RA) taken as inflammatory control, and osteoarthritis (OA) as non-inflammatory control patients:

- (i) *C. trachomatis* ReA (n=13) was defined by the presence of asymmetrical mono/oligoarthritis and evidence of *C. trachomatis* infection (positive culture or DNA amplification)(median age, 26 years; interquartile range (IQR) 21-33, 2 were females, median number of SF leucocytes, 13700/mm<sup>3</sup> (9400–23900), median duration of arthritis, 14 days (IQR 7–46) and median number of active joints, 2 (IQR 1–3.3)).
- (ii) Rheumatoid arthritis (RA) (n=20) (median age, 67 years (IQR 54–79), 17 females, median number of SF leucocytes, 7700/mm<sup>3</sup> (IQR 5738–12613)).
- (iii)Osteoarthritis (OA)(n=17)(median age, 73 years (IQR 64–78), 11 females, median number of SF leucocytes, 300/mm<sup>3</sup> (IQR 150-463)).

The levels of cytokine concentrations in SF were determined by sandwich ELISA techniques. In *C. trachomatis* ReA patients, the SF concentrations of IFN- $\gamma$  and IL-17 were significantly higher than in OA patients (median 13.6 pg/ml, IQR 2.33–31.3 vs. median 0 pg/ml, IQR 0–1.76  $p<0.005$  and median 5.7 pg/ml, IQR 0–25.4 vs. median 0 pg/ml, IQR 0–0,  $p<0.005$ , respectively). No significant difference was found between *C. trachomatis* ReA and RA patients (Fig. 1). A positive correlation (Rho=0.74,  $p=0.011$ ) was found between the levels of IFN- $\gamma$  and IL-17 in SF of *C. trachomatis* ReA patients. The levels of cytokines modulating IFN- $\gamma$  and IL-17 expression such as IL-1 $\beta$ , IL-6, IL-12p70 and IL-23(p19/p40), (3, 4) were also determined. The concentrations of IL-1 $\beta$  in the SF of *C. trachomatis* ReA (median 6.5 pg/ml, IQR 1.6–15.2) were significantly higher than in OA patients (median 0 pg/ml, IQR 0-0.1,  $p<0.0001$ ) (Fig. 1). A positive correlation (Rho=0.70,  $p=0.02$ ) was found between the levels of IL-1 $\beta$  and IL-17 in SF of *C. trachomatis* ReA patients. There was no significant difference between ReA and OA regarding the other cytokines, mainly because of wide interindividual variations



**Fig. 1.** Levels of IFN- $\gamma$ , IL-17, IL-6, and IL-1 $\beta$  in the SF of patients with *C. trachomatis* ReA, RA and OA. Levels were determined by ELISA. Horizontal bars within boxes show the median, boxes show the interquartile range and vertical bars show the 95% confidence interval (values above and below these levels were plotted separately). Comparison between two groups was made only when the Kruskal-Wallis test yielded statistically significant results. \*\* $p<0.005$ ; \*\*\* $p<0.0001$  compared with OA patients (Mann-Whitney test).

## Letters to the Editor

in IL-6 concentrations and non detectable levels of IL-12p70 and IL-23 (data not shown).

This is the first study reporting the presence of IL-17 in the SF of patients with *C. trachomatis* ReA. Both IFN- $\gamma$  and IL-17 were detected and a positive correlation was found between their levels indicating possible similar regulation by the local cytokine milieu in *C. trachomatis* ReA joints.

The role of IFN- $\gamma$  and IL-17 in the SF from *C. trachomatis* ReA patients is unclear. IFN- $\gamma$  is well known for its antichlamydial activity but its median concentration (13.6 pg/ml) was lower than values reported to be efficient *in vitro*. Indeed, high levels of IFN- $\gamma$  (2 ng/ml) promoted the destruction of *Chlamydia* whereas lower levels (0.2 ng/ml) induced the formation of persistent forms (5). However it is difficult to extrapolate results obtained *in vitro* to the environment of an arthritic joint. The same remark is valid for IL-17 concentrations found in SF from *C. trachomatis* ReA patients. IL-17 is well known for its role in joint destruction (6) but recent findings indicate that IL-17 may also contribute to protection against intracellular bacteria (7, 8).

S. BAS, PhD<sup>1,2</sup>  
L. NEFF, PhD<sup>1,3</sup>  
S. VIATTE, MD<sup>1</sup>  
M. VUILLET<sup>1</sup>  
U. SPENATO<sup>1</sup>

P.-A. GUERNE, MD<sup>1</sup>  
M. MICHEL, MD<sup>4</sup>  
J.-M. TIERCY, PhD<sup>5</sup>  
I. BUTRIMIENE, MD<sup>6</sup>  
C. GABAY, MD<sup>1,3</sup>

<sup>1</sup>Division of Rheumatology, Department of Internal Medicine, <sup>2</sup>Genetics and Laboratory Medicine Department, <sup>3</sup>Department of Pathology and Immunology, <sup>4</sup>Division of Hematology, Department of Internal Medicine, <sup>5</sup>Transplantation Immunology Unit/LNRH, Department of Internal Medicine, University Hospitals, Geneva, Switzerland; <sup>6</sup>Department of Rheumatology, Institute of Experimental and Clinical Medicine, Vilnius University, Vilnius, Lithuania.

This work was supported by grants from Novartis, Albert-Boeni, de Reuter Foundations, and SwissLife as well as by grants 3200B0-107883 (to S.B.) and 320000-119728 (to C.G.) from the Swiss National Science Foundation (SNSF).

Address correspondence to: Dr Sylvette Bas, Division of Rheumatology, University Hospitals, 1211 Geneva 14, Switzerland.  
E-mail: sylvette.bas@hcuge.ch  
(reprints will not be available from the author)

Competing interests: none declared.

### References

1. GIRSCHICK HJ, GUILHERME L, INMAN RD *et al.*: Bacterial triggers and autoimmune rheumatic diseases. *Clin Exp Rheumatol* 2008; 26: S12-7.
2. SINGH R, AGGARWAL A, MISRA R: Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthritis. *J Rheumatol* 2007; 34: 2285-90.
3. VANDEN EIJNDEN S, GORIELY S, DE WIT D, WILLEMS F, GOLDMAN M: IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. *Eur J Immunol* 2005; 35: 469-75.
4. HOEVE MA, SAVAGE ND, DE BOER T *et al.*: Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. *Eur J Immunol* 2006; 36: 661-70.
5. BEATTY WL, BYRNE GI, MORRISON RP: Morphologic and antigenic characterization of interferon gamma-mediated persistent *Chlamydia trachomatis* infection *in vitro*. *Proc Natl Acad Sci USA* 1993; 90: 3998-4002.
6. LUBBERTS E, KOENDERS MI, VAN DEN BERG WB: The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. *Arthritis Res Ther* 2005; 7: 29-37.
7. KHADER SA, BELL GK, PEARL JE *et al.*: IL-23 and IL-17 in the establishment of protective pulmonary CD4<sup>+</sup> T cell responses after vaccination and during *Mycobacterium tuberculosis* challenge. *Nat Immunol* 2007; 8: 369-77.
8. SCRIBA TJ, KALSDORF B, ABRAHAMS DA *et al.*: Distinct, specific IL-17- and IL-22-producing CD4<sup>+</sup> T cell subsets contribute to the human anti-mycobacterial immune response. *J Immunol* 2008; 180: 1962-70.